Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone

Authors

  • Louis Hoffart MD MSc,

    Corresponding author
    1. Ophthalmology Department, Aix-Marseille University, Hopital de la Timone, Marseille, France,
    2. Institut de Neurosciences Cognitives de la Méditerranée (CNRS 6193) Aix-Marseille University, 3 Faculty of Medicine, Aix-Marseille university, France, and
    Search for more papers by this author
  • Frederic Matonti MD MSc,

    1. Ophthalmology Department, Aix-Marseille University, Hopital de la Timone, Marseille, France,
    2. Institut de Neurosciences Cognitives de la Méditerranée (CNRS 6193) Aix-Marseille University, 3 Faculty of Medicine, Aix-Marseille university, France, and
    Search for more papers by this author
  • John Conrath MD PhD,

    1. Ophthalmology Department, Aix-Marseille University, Hopital de la Timone, Marseille, France,
    2. Institut de Neurosciences Cognitives de la Méditerranée (CNRS 6193) Aix-Marseille University, 3 Faculty of Medicine, Aix-Marseille university, France, and
    Search for more papers by this author
  • Laurent Daniel MD PhD,

    1. Faculty of Medicine, Aix-Marseille University, France.
    Search for more papers by this author
  • Bernard Ridings MD,

    1. Ophthalmology Department, Aix-Marseille University, Hopital de la Timone, Marseille, France,
    2. Institut de Neurosciences Cognitives de la Méditerranée (CNRS 6193) Aix-Marseille University, 3 Faculty of Medicine, Aix-Marseille university, France, and
    Search for more papers by this author
  • Guillaume S Masson PhD,

    1. Institut de Neurosciences Cognitives de la Méditerranée (CNRS 6193) Aix-Marseille University, 3 Faculty of Medicine, Aix-Marseille university, France, and
    Search for more papers by this author
  • Frederic Chavane PhD

    1. Institut de Neurosciences Cognitives de la Méditerranée (CNRS 6193) Aix-Marseille University, 3 Faculty of Medicine, Aix-Marseille university, France, and
    Search for more papers by this author

Dr Louis Hoffart, Service d'ophtalmologie, Hôpital d'adultes de la Timone, 264 rue Saint Pierre, 13385 Marseille cedex 5, France. Email: louis.hoffart@ap-hm.fr

Abstract

Background:  To compare the effects of different doses of bevacizumab with both saline and dexamethasone on inflammatory angiogenesis in the rat cornea induced by small chemical lesions.

Methods:  Corneal chemical cauterization was performed on 24 rats. Animals were divided randomly into six groups and received a daily subconjunctival injection for 7 days of: balanced salt solution 0.1 mL or dexamethasone phosphate 4 mg/day or bevacizumab 2.5 mg/day, 3.75 mg/day, 5.0 mg/day or bevacizumab 5.0 mg/day + dexamethasone phosphate 4 mg/day. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer-assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization.

Results:  At final examination, the dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups showed a significant lowering in corneal opacity score as compared with control (P = 0.024, P = 0.006 and P = 0.013, respectively). Also, a significant reduction on new vessels size score was observed. Surface of corneal neovascularization was significantly reduced in dexamethasone, bevacizumab 5.0 mg/day and dexamethasone + bevacizumab groups compared with control (P = 0.045, P = 0.047 and P = 0.044, respectively).

Conclusion:  Our study demonstrates the ability of a 5.0 mg/day bevacizumab subconjunctival injection, in monotherapy or associated with dexamethasone, to cause a short-term involution of corneal neovascularization after corneal alkali burn. Combination of both of these treatments may have advantages to monotherapy approaches.

Ancillary